NO20034322L - Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister - Google Patents
Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonisterInfo
- Publication number
- NO20034322L NO20034322L NO20034322A NO20034322A NO20034322L NO 20034322 L NO20034322 L NO 20034322L NO 20034322 A NO20034322 A NO 20034322A NO 20034322 A NO20034322 A NO 20034322A NO 20034322 L NO20034322 L NO 20034322L
- Authority
- NO
- Norway
- Prior art keywords
- dementia
- treatment
- neurodegenerative diseases
- lhrh antagonists
- intermediate doses
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 1
- 229960003230 cetrorelix Drugs 0.000 abstract 1
- 108700008462 cetrorelix Proteins 0.000 abstract 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034322D0 NO20034322D0 (no) | 2003-09-26 |
| NO20034322L true NO20034322L (no) | 2003-09-26 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034322A NO20034322L (no) | 2001-04-30 | 2003-09-26 | Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (enExample) |
| EP (1) | EP1392348B1 (enExample) |
| JP (1) | JP2004529207A (enExample) |
| KR (1) | KR20040000446A (enExample) |
| CN (1) | CN1317030C (enExample) |
| AT (1) | ATE400287T1 (enExample) |
| AU (1) | AU2002310788B2 (enExample) |
| BG (1) | BG108339A (enExample) |
| BR (1) | BR0209290A (enExample) |
| CA (1) | CA2444876A1 (enExample) |
| CZ (1) | CZ20033167A3 (enExample) |
| DE (1) | DE60227507D1 (enExample) |
| DK (1) | DK1392348T3 (enExample) |
| ES (1) | ES2307760T3 (enExample) |
| HU (1) | HUP0400067A2 (enExample) |
| IL (1) | IL156777A0 (enExample) |
| MX (1) | MXPA03008666A (enExample) |
| NO (1) | NO20034322L (enExample) |
| NZ (1) | NZ544417A (enExample) |
| PL (1) | PL362319A1 (enExample) |
| PT (1) | PT1392348E (enExample) |
| RU (1) | RU2319501C2 (enExample) |
| SI (1) | SI1392348T1 (enExample) |
| SK (1) | SK14512003A3 (enExample) |
| UA (1) | UA80679C2 (enExample) |
| WO (1) | WO2002102401A1 (enExample) |
| ZA (1) | ZA200305326B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| DK1300398T3 (da) | 2000-07-05 | 2006-07-17 | Astellas Pharma Inc | Propan-1,3-dionderivat |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| JP4595938B2 (ja) | 2004-06-04 | 2010-12-08 | アステラス製薬株式会社 | プロパン−１，３−ジオン誘導体又はその塩 |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| ES2445791T3 (es) | 2006-10-21 | 2014-03-05 | Abbvie Deutschland Gmbh & Co Kg | Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3 |
| US20100204143A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| WO2009049742A2 (en) * | 2007-09-11 | 2009-04-23 | Mondobiotech Laboratories Ag | Use of melanotrophin-potentiating factor as a therapeutic agent |
| EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| CA2726247C (en) * | 2008-05-29 | 2018-06-26 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| EP0901489A1 (en) * | 1996-05-20 | 1999-03-17 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| NZ515460A (en) * | 1999-05-14 | 2004-06-25 | Neurocrine Biosciences Inc | Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| DE60022769T2 (de) * | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| AU2001248760A1 (en) | 2000-04-13 | 2001-10-30 | Takeda Chemical Industries Ltd. | Preventives/remedies for alzheimer's disease |
| DK1300398T3 (da) | 2000-07-05 | 2006-07-17 | Astellas Pharma Inc | Propan-1,3-dionderivat |
-
2002
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2444876A1 (en) | 2002-12-27 |
| US7288517B2 (en) | 2007-10-30 |
| PT1392348E (pt) | 2008-09-09 |
| PL362319A1 (en) | 2004-10-18 |
| KR20040000446A (ko) | 2004-01-03 |
| BG108339A (bg) | 2004-11-30 |
| HUP0400067A2 (hu) | 2004-04-28 |
| WO2002102401A1 (en) | 2002-12-27 |
| JP2004529207A (ja) | 2004-09-24 |
| UA80679C2 (en) | 2007-10-25 |
| ZA200305326B (en) | 2003-07-30 |
| ES2307760T3 (es) | 2008-12-01 |
| SI1392348T1 (sl) | 2008-12-31 |
| DE60227507D1 (de) | 2008-08-21 |
| NZ544417A (en) | 2008-03-28 |
| HK1072000A1 (en) | 2005-08-12 |
| EP1392348A1 (en) | 2004-03-03 |
| MXPA03008666A (es) | 2004-10-15 |
| ATE400287T1 (de) | 2008-07-15 |
| US20020177556A1 (en) | 2002-11-28 |
| AU2002310788B2 (en) | 2007-04-05 |
| RU2319501C2 (ru) | 2008-03-20 |
| BR0209290A (pt) | 2004-07-13 |
| NO20034322D0 (no) | 2003-09-26 |
| CN1575185A (zh) | 2005-02-02 |
| EP1392348B1 (en) | 2008-07-09 |
| SK14512003A3 (sk) | 2004-08-03 |
| CN1317030C (zh) | 2007-05-23 |
| IL156777A0 (en) | 2004-02-08 |
| RU2003134949A (ru) | 2005-02-10 |
| CZ20033167A3 (cs) | 2004-08-18 |
| DK1392348T3 (da) | 2008-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034322D0 (no) | Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister | |
| TR200001608T2 (tr) | Amiloidojenik hastalığın önlenmesi ve tedavisi | |
| NO20022531D0 (no) | Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer | |
| LU92854I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil | |
| LTPA2015001I1 (lt) | Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai | |
| WO2002002506A8 (en) | Compounds to treat alzheimer's disease | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| NO20026199D0 (no) | Forbindelser for behandling av Alzheimers sykdom | |
| EA200400352A1 (ru) | Органолептически приемлемые распадающиеся во рту композиции | |
| TNSN04165A1 (en) | Substituted hydroxyethylamines | |
| EA200301223A1 (ru) | Лекарственные формы окскарбазепина | |
| ATE506959T1 (de) | Verwendung von il-18 inhibitoren | |
| JO2207B1 (en) | Pharmaceutical radiological compounds to diagnose Alzheimer's disease | |
| NO20000771L (no) | Anvendelse av fankinon for behandling av Alzheimers sykdom | |
| DE60028928D1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
| BR0000486A (pt) | Antagonistas do neuropeptìdeo y | |
| NO20053341D0 (no) | Hindring og behandling av Alzheimers sykdom. | |
| DE60117541D1 (de) | Candesartan zur Behandlung von Migräne | |
| MXPA03008406A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina. | |
| YU9099A (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease | |
| HK1063639A (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| AU2002319451A1 (en) | Therapeutic strategies for prevention and treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |